摘要
目的:系统评价血府逐瘀制剂治疗乳腺增生症的有效性,为临床合理应用该类制剂提供循证参考。方法:计算机检索中国生物医学文献数据库、中文科技期刊全文数据库、万方数据库、中国期刊全文数据库、Embase及MedLine等数据库,收集血府逐瘀制剂(汤剂、胶囊及口服液)联合其他治疗手段(观察组)与其他药物联合其他治疗手段或随访(对照组)的随机对照试验。在质量评价与文献提取的基础上,采用统计软件RevMan 5.3进行文献荟萃分析。结果:最终将7篇文献纳入此次研究,共871例患者。Meta分析结果显示,观察组患者的有效率(OR=4.62,95%CI=3.08~6.93,P<0.000 01)、治愈率[OR=2.83,95%CI=1.94~4.13,P<0.000 01(6篇文献);OR=2.32,95%CI=1.54~3.49,P<0.000 1(剔除异质性研究后的5篇文献)]明显优于对照组,差异均有统计学意义。结论:与其他药物联合其他治疗手段比较,血府逐瘀制剂联合其他治疗手段治疗乳腺增生症更有效。
OBJECTIVE： To systematically review the effectiveness of Xuefuzhuyu preparation in treatment of cyclomastopathy, so as to provide evidence-based references for the rational application of this kind of preparations. METHODS： CBM, VIP, Wanfang database, CNKI, Embase and MedLine were retrieved to collect randomized controlled trials between Xuefuzhuyu preparation （decoction, capsule and oral liquid） combined with other treatment （observation group） and other drugs combined with some therapeutic options or follow up （control group）. On the basis of quality evaluation and literature extraction, the RevMan 5.3 was adopted to conduct Meta analysis. RESULTS： 7 studies were involved, including 871 patients. Results of Meta analysis indicated the total effective rate （ OR = 4. 62, 95 % CI = 3.08-6.93, P 〈 0. 000 01 ） and cure rate ~ OR = 2. 83,95 % CI = 1.94-4. 13, P 〈 0. 000 01 （ 6 studies） ; OR = 2. 32,95 % CI = 1.54-3.49, P 〈 0. 000 1 （ 5 studies after excluding heterogeneity） ] of observation group were significantly higher than those of the control group, with statistically significance differences. CONCLUSIONS： The efficacy of Xuefuzhuyu preparation combined with other therapeutic options in treatment cvclomastopathv is better than that of dru^s combined with other treatment methods.
出处
《中国医院用药评价与分析》
2017年第12期1663-1666,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
新疆医科大学人文社会科学基金项目改革与发展专项(No.2017XYFG55)
